Author/Authors :
Jancoriene Ligita نويسنده Vilnius University Hospital Santaros Klinikos, Centre of
Infectious Diseases, Vilnius, Lithuania , Polubenko Katazyna نويسنده Faculty of Medicine, Vilnius University, Vilnius,
Lithuania , Kazenaite Edita نويسنده Faculty of Medicine, Vilnius University, Vilnius,
Lithuania , Buivydiene Arida نويسنده Faculty of Medicine, Vilnius University, Vilnius,
Lithuania , Jakutiene Jolita نويسنده Vilnius University Hospital Santaros Klinikos, Centre of
Hepatology, Gastroenterology and Dietetics, Vilnius,
Lithuania , Tolmane Ieva نويسنده Riga East University Hospital, Infectology Center of
Latvia, Hepatology Department, Riga, Latvia , Jeruma Agita نويسنده Riga East University Hospital, Infectology Center of
Latvia, Hepatology Department, Riga, Latvia , Radzisauskiene Daiva نويسنده Vilnius University Hospital Santaros Klinikos, Centre of
Infectious Diseases, Vilnius, Lithuania , Mockiene Evelina نويسنده Faculty of Medicine, Vilnius University, Vilnius,
Lithuania , Ambrozaitis Arvydas نويسنده Vilnius University Hospital Santaros Klinikos, Centre of
Infectious Diseases, Vilnius, Lithuania
Abstract :
Background The current international multicentre open-label,
uncontrolled, real-world retrospective study aimed at evaluating the
effectiveness and safety of ombitasvir / paritaprevir / ritonavir +
dasabuvir ± ribavirin (3D therapy) in treatment-naive and
treatment-experienced hepatitis C virus (HCV) genotype 1-infected (GT1)
patients. Methods Adult patients with chronic HCV GT1 infection,
scheduled for 3D therapy according to therapeutic guidelines, were
eligible. Demographic and clinical data were collected retrospectively
by reviewing individuals health records. The primary effectiveness
endpoint was the sustained virological response at 12 weeks following
the end of treatment (SVR12). Results The participants in the current
study consisted of 134 patients with HCV GT1 infection, including 10
liver transplant recipients. SVR12 was achieved in 120 (96.8%)
non-transplant and all liver transplant patients (100%). Significant
improvement in liver function tests were observed. Among 4 treatment
failures, 2 patients were non-responders and 2 patients relapsed.
OBV/PTV/r + DSV ± RBV regimen was well tolerated in most patients with
treatment discontinuation due to adverse events in 3 patients. The most
frequent adverse events were asthenia (25.8%), fatigue (16.1%), skin
pruritus (12.9%), and dyspepsia (11.3%). Conclusions The current
real-life study demonstrated the effectiveness and safety of OBV/PTV/r +
DSV ± RBV in patients with HCV GT1, including patients with cirrhosis, a
liver transplant recipient and the one who failed previous antiviral
therapies.
